Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRB | P28702 | 9/20 | 0.50 |
| ▸ | RXRA | P19793 | 9/20 | 0.50 |
| ▸ | RXRG | P48443 | 6/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.43 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7847131 | 0.97 | RXRA (0.50) | RXRBRXRARXRGMRGPRX4MCL1 | |
| SCHEMBL9719997 | 0.85 | RXRA (0.55) | RXRBRXRARXRGMRGPRX4MCL1 | |
| SCHEMBL11015470 | 0.83 | RXRB (0.50) | RXRBRXRARXRGMRGPRX4MCL1 | |
| SCHEMBL5456652 | 0.83 | RXRA (0.50) | RXRBRXRARXRGMRGPRX4MCL1 | |
| SCHEMBL2416358 | 0.83 | RXRB (0.50) | RXRBRXRARXRGMRGPRX4MCL1 | |
| SCHEMBL12968228 | 0.81 | PTGES (0.55) | RXRBRXRARXRGMRGPRX4MCL1 | |
| SCHEMBL15625773 | 0.80 | S1PR5 (0.54) | RXRBRXRARXRGMRGPRX4MCL1 | |
| SCHEMBL6480708 | 0.79 | RXRA (0.50) | RXRBRXRARXRGMRGPRX4MCL1 | |
| SCHEMBL5448918 | 0.79 | RXRA (0.50) | RXRBRXRARXRGMRGPRX4MCL1 | |
| SCHEMBL9512276 | 0.79 | RXRA (0.54) | RXRBRXRARXRGMRGPRX4MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100408575-C | Aryl-8-azabicyclo[3,2,1]octanes for treating depression | WYETH CORP (US) | 2008-08-06 | — | — | CN | disclosed |
| EP-1390364-B1 | ARYL-8-AZABICYCLO 3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION | WYETH CORP (US) | 2004-09-29 | — | — | EP | disclosed |
| CN-1509287-A | Aryl-8-azabicyclo[3,2,1]octanes for treating depression | — | 2004-06-30 | — | — | CN | disclosed |
| EP-1390364-A1 | ARYL-8-AZABICYCLO 3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION | Wyeth (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6632824-B2 | Have the ability to act at the 5-HT transporter. | WYETH | 2003-10-14 | — | — | US | disclosed |
| US-20030032645-A1 | Aryl-8-azabicyclo [3.2.1] octanes for the treatment of depression | WYETH | 2003-02-13 | — | — | US | disclosed |
| WO-2002096906-A1 | ARYL-8-AZABICYCLO[3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION | WYETH (US) | 2002-12-05 | — | — | WO | disclosed |
| US-6291683-B1 | AS ANTIDEPRESSANTS | AMERICAN HOME PRODUCTS CORP | 2001-09-18 | — | — | US | disclosed |
| EP-1070050-A1 | N-ARYLOXYETHYL-INDOLY-ALKYLAMINES FOR THE TREATMENT OF DEPRESSION (5-HT1A RECEPTOR ACTIVE AGENTS) | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-01-24 | — | — | EP | disclosed |
| US-6121307-A | SIDE EFFECT REDUCTION; ADMINISTERING TO TREAT DEPRESSION | AMERICAN HOME PRODUCTS CORP. (US) | 2000-09-19 | — | — | US | disclosed |
| WO-1999051575-A1 | N-ARYLOXYETHYL-INDOLY-ALKYLAMINES FOR THE TREATMENT OF DEPRESSION (5-HT1A RECEPTOR ACTIVE AGENTS) | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032645-A1 | Aryl-8-azabicyclo [3.2.1] octanes for the treatment of depression | HTR1A, HTR1D, HTR2C | RXRB 385/4885RXRA 376/4885RXRG 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.